Biotechnology

Lakefront Biotherapeutics

RBC Capital Analyst Maintains Hold Rating for Lakefront Biotherapeutics

Lakefront Biotherapeutics released FY2026 Q1 earnings on May 6 After-Market EST, actual revenue USD 7.427 M (forecast USD 33.65 M), actual EPS USD 0.2521 (forecast USD -1.4974)

LKFT.US released FY2025 Q1 earnings on May 6 After-Market (BJT), actual revenue USD 81.16 M (forecast USD 74.55 M), actual EPS USD -2.5221

Lakefront Biotherapeutics released FY2024 earnings on March 26 After-Market EST, actual revenue USD 296.59 M (forecast USD 298.32 M), actual EPS USD 1.2082

LKFT.US released FY2024 Q2 earnings on July 24 After-Market (BJT), actual revenue USD 83.42 M (forecast USD 64.92 M), actual EPS USD 0.1459

LKFT.US released FY2025 Q2 earnings on July 24 (BJT), actual revenue USD 76.42 M (forecast USD 82.55 M), actual EPS USD -1.8767

Lakefront Biotherapeutics released FY2025 Semi-Annual earnings on July 24 (EST), actual revenue USD 158.01 M, actual EPS USD -4.4302

LKFT.US released FY2024 Q4 earnings on March 26 After-Market (BJT), actual revenue USD 0 (forecast USD 72.71 M), actual EPS USD 0

Lakefront Biotherapeutics released FY2025 earnings on March 26 Pre-Market (EST), actual revenue USD 1.282 B (forecast USD 328.88 M), actual EPS USD 5.6106

Lakefront Biotherapeutics released FY2023 earnings on March 26 Pre-Market EST, actual revenue USD 259.95 M (forecast USD 607.07 M), actual EPS USD 3.4842

Lakefront Biotherapeutics released FY2025 Q3 earnings on November 5 Pre-Market EST, actual revenue USD 83.45 M (forecast USD 81.02 M), actual EPS USD -3.5977 (forecast USD -0.5622)

LKFT.US released FY2025 9 Months Earnings on November 5 Pre-Market (BJT), actual revenue USD 241.04 M, actual EPS USD -7.9967

LKFT.US released FY2025 Q4 earnings on March 26 Pre-Market (BJT), actual revenue USD 1.058 B (forecast USD 83.8 M), actual EPS USD 13.9381

LKFT.US released FY2024 Semi-Annual earnings on July 24 After-Market (BJT), actual revenue USD 150.85 M, actual EPS USD 1.6186

HCW Biologics

P3 Health Partners

Murano Global BV

Auddia

Super League Enterprise

Trio-Tech Int

Ernexa Therapeutics

Robostrategy

Jiade

LKFT

RBC Capital analyst Brian Abrahams has maintained a Hold rating on Lakefront Biotherapeutics (LKFT) with a price target of $28.00. Abrahams, a 5-star analyst, has an average return of 10.1% and a 51.10% success rate. The overall analyst consensus for Lakefront Biotherapeutics is a Moderate Sell, with an average price target of $25.00.

Tip Ranks

ROYAL BANK OF CANADA

Gilead Sciences

Acadia Pharma

BioCryst Pharma

RBC Capital Sticks to Its Hold Rating for Lakefront Biotherapeutics (LKFT)

GLPG

ARKG

SBIO

LABU

Galapagos NV shareholders approved a name change to Lakefront Biotherapeutics and a governance overhaul during their meetings on April 28, 2026. Key changes include the appointment of CEO Henry Gosebruch as executive director, new independent directors, and a renewed focus on sustainability reporting. The board was authorized to repurchase shares and increase capital by 20%. The company aims to support its transformation and growth phase, with Gino Santini as the new chair. Current analyst rating for GLPG stock is a Hold with a price target of $28.00.

Galapagos NV

VanEck Biotech ETF

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

VG Health

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Galapagos Shareholders Approve Name Change to Lakefront Biotherapeutics and Broad Governance Overhaul

Galapagos (NASDAQ:GLPG) is set to announce its Q1 2026 earnings on May 6, with analysts expecting a loss of $0.13 per share and revenue of $39.58 million. The company reported $13.92 EPS and $1.06 billion revenue in its last quarter. Currently, GLPG stock is trading at $28.42, with a market cap of $1.87 billion. Analysts have mixed ratings, with one Strong Buy, five Holds, and one Sell. Institutional investors hold 32.46% of the stock, reflecting increased interest in the company.

Market Beat

UBS Group AG

Raymond James Financial

Man Group PLC

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

Galapagos (GLPG) Expected to Announce Quarterly Earnings on Wednesday

Galapagos NV (NASDAQ:GLPG) experienced a 20.4% increase in short interest in March, totaling 1,096,114 shares as of March 31. This represents 1.7% of the company's stock being short sold, with a short-interest ratio of 5.0 days based on an average daily volume of 218,377 shares. The stock traded at $29.28, with a market cap of $1.93 billion. Analysts have mixed ratings, with a consensus rating of "Hold" and a target price of $36.50. Institutional investors own 32.46% of the stock, reflecting significant interest in the company.

Ameriprise Financial

MarketWise

Short Interest in Galapagos NV (NASDAQ:GLPG) Expands By 20.4%

Galapagos NV (NASDAQ:GLPG) shares fell below their 200-day moving average of $32.63, trading at $28.93. Analysts have mixed opinions, with one Strong Buy, five Holds, and one Sell rating. The average target price is $36.50. The company reported $13.92 EPS and $1.06 billion in revenue last quarter. Institutional investors hold 32.46% of the stock. Galapagos focuses on developing small-molecule therapies for chronic diseases and has a market cap of $1.91 billion.

Galapagos (NASDAQ:GLPG) Stock Crosses Below 200 Day Moving Average   - Time to Sell?

Galapagos has entered a binding framework agreement with Gilead Sciences related to Gilead's $1.675 billion acquisition of Ouro Medicines. This deal involves co-developing gamgertamig, a T cell engager for autoimmune diseases, with Galapagos funding 50% of the acquisition and development costs. Gilead will handle global commercialization outside certain territories, paying Galapagos tiered royalties. The agreement allows Galapagos to utilize $500 million independently for strategic moves, including potential share buybacks. Analysts rate GLPG stock as a Buy with a $32.00 price target, while Spark's AI Analyst gives it a Neutral rating due to financial concerns.

iShares Global Healthcare

Galapagos Strikes New Gilead Deal to Co-Develop Gamgertamig and Unlock $500 Million for Strategic Moves

Lakefront Biotherapeutics(LKFT.US)

RBC Capital Sticks to Its Hold Rating for Lakefront Biotherapeutics (LKFT)

Galapagos Shareholders Approve Name Change to Lakefront Biotherapeutics and Broad Governance Overhaul

Galapagos (GLPG) Expected to Announce Quarterly Earnings on Wednesday

Short Interest in Galapagos NV (NASDAQ:GLPG) Expands By 20.4%

Galapagos (NASDAQ:GLPG) Stock Crosses Below 200 Day Moving Average - Time to Sell?

Galapagos Strikes New Gilead Deal to Co-Develop Gamgertamig and Unlock $500 Million for Strategic Moves